

Clinical trials of multi target TKI for advanced breast cancer (metastatic) in HR+ HER2-

TrialResults-center www.trialresultscenter.org

1 TKI inhibitor FGFR VEGFR PDGFR

Trial	Treatments	Patients	Trials design and methods
Dovitinib + Fulvestrant vs placebo + Fulvestrant			
NCT01528345 <i>ongoing</i> [NCT01528345] n=NA follow-up:	Dovitinib Combined With Fulvestrant versus placebo + fulvestrant alone	postmenopausal patients with locally advanced or metastatic, HER2- and HR+ breast cancer not amenable to curative treatment by surgery or radiotherapy, and whose disease has progressed on or after prior endocrine therapy	Parallel groups double-blind

References

NCT01528345, :

Musulino A, Campone M, Neven P, Denduluri N, Barrios CH, Cortes J, Blackwell K, Soliman H, Kahan Z, Bonnefoi H, Squires M, Zhang Y, Deudon S, Shi MM, Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR⁺, HER2⁻ breast cancer that had progressed during or after prior endocrine therapy. *Breast Cancer Res* 2017;19:18 [28183331]

2 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.